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Abstract. 
Ligands acting at multiple dopamine receptors hold potential as therapeutic agents for a 
number of neurodegenerative disorders. Specifically, compounds able to bind at D1R and 
D2R with high affinity could restore the effects of dopamine depletion and enhance motor 
activation on degenerated nigrostriatal dopaminergic systems. We have directed our research 
towards the synthesis and characterisation of heterocycle-peptide hybrids based on the 
indolo[2,3-a]quinolizidine core. This privileged structure is a water-soluble and synthetically 
accessible scaffold with affinity for diverse GPCRs. Herein we have prepared a solid-phase 
combinatorial library of 80 indoloquinolizidine-peptides to identify compounds with 
enhanced binding affinity at D2R, a receptor that is crucial to re-establish activity on 
dopamine-depleted degenerated GABAergic neurons. We applied computational tools and 
high-throughput screening assays to identify 9a{1,3,3} as a ligand for dopamine receptors 
with nanomolar affinity and agonist activity at D2R. Our results validate the application of 
indoloquinolizidine-peptide combinatorial libraries to fine-tune the pharmacological profiles 
of multiple ligands at D1 and D2 dopamine receptors. 
 
Keywords: privileged scaffolds, solid-phase synthesis, GPCRs, neurodegenerative diseases, 
heterocycles. 
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Introduction. 
The solid-phase synthesis of combinatorial libraries and their screening has proven effective 
for the identification of bioactive compounds and their subsequent optimisation, especially 
when the synthetic routes have sufficient generality to produce novel analogues of interest.1-6 
We have directed our research towards privileged scaffolds as templates for biologically 
active molecules at multiple therapeutic targets, and described the synthesis and 
characterisation of heterocycle-peptide hybrids as ligands for G-protein coupled receptors 
(GPCRs).7,8 Among GPCRs, structures simultaneously binding at multiple dopamine receptor 
subtypes hold potential as therapeutic agents for the treatment of neurodegenerative 
disorders, such as Parkinson’s disease (PD).9,10 Dual molecules with ability to bind both 
dopamine D1R and D2R could restore the effects of dopamine depletion and enhance motor 
activation on degenerated nigrostriatal dopaminergic systems via simultaneous activation of 
the direct pathway (i.e. via D1R on striatonigral neurons) and repression of the inhibitory 
indirect pathway (i.e. via D2R on striatopallidal GABAergic neurons).11 Our group has 
reported the preparation of ergolene-peptide12,13 and indolo[2,3-a]quinolizidine-peptide 
hybrids as ligands for dopamine receptors.14,15 The indolo[2,3-a]quinolizidine structure is a 
water-soluble and synthetically accessible scaffold resembling indoloazecine and tetrahydro-
β-carboline systems with affinity for a number of GPCRs.16 Our first studies with 
indoloquinolizidine-peptides identified a number of compounds with medium to high affinity 
for D1R and D2R. While those compounds presented submicromolar affinity at D1R, their 
affinities at D2R were limited to the low micromolar range. Herein we have designed a solid-
phase combinatorial library of 80 new indoloquinolizidine-peptide hybrids to enhance their 
binding affinity at D2R, a receptor that is crucial to re-establish activity on dopamine-depleted 
degenerated GABAergic neurons, that could lead to potential dual ligands for D1R and D2R. 
We have screened our library using radioligand binding and ERK1/2 phosphorylation assays 
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to identify new indoloquinolizidine-peptides maintaining high affinities at D1R while 
achieving enhanced nanomolar binding affinity and agonist activity at D2R. 
 
Results and Discussion. 
Library design. Indolo[2,3-a]quinolizidines are excellent structures for combinatorial 
medicinal chemistry because of their straightforward synthesis and diverse pharmacological 
properties. We previously optimised the synthesis of indolo[2,3-a]quinolizidine carboxylic 
acids based on the protocol of Wenkert et al. (acid cyclization of N-trypthophyl-1,4-
dihydropyridines to afford indoloquinolizidines).17 Both cis (1) and trans (2) diasteroisomers 
(Figure 1a) are racemic compounds and can be prepared in multigram scale with high purities 
after five synthetic steps. In order to facilitate the preparation of combinatorial libraries of 
indoloquinolizidine-peptides (3, Figure 1b), we optimised the incorporation of 1 and 2 to 
solid-phase peptide synthesis (SPPS). To the best of our knowledge, our approach represents 
the first adaptation of indolo[2,3-a]quinolizidines to solid-phase chemistry. We prepared 
indoloquinolizidine-peptides with variable stereochemistry at C3 and C12b of the indolo[2,3-
a]quinolizidine core and different tripeptides for enhanced affinity at D1R and D2R. Previous 
studies with indoloquinolizidine-peptides indicated the heterocyclic core as the major 
responsible for the interaction at the binding sites while tripeptides mainly interacted with the 
extracellular regions of dopamine receptors. In the present work, we explored different 
peptides around the indoloquinolizidine core to increase the binding affinity at D2R and 
generate multiple D1/D2 high-affinity ligands. 
 
Figure 1. a) Building blocks employed in the synthesis of the library; b) general structure of 
indoloquinolizidine-peptides. 
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We have designed a library of novel indoloquinolizidine-tripeptides using combinations of 9 
different amino acids. As C-terminal amino acids (AA3, Figure 1a), we employed neutral and 
positively-charged cyclic amino acids (i.e. Pro and Amp) as well as one linear positively-
charged amino acid (Lys). This selection was based on the electrostatic nature of the 
extracellular surface of dopamine receptors. As shown in the molecular electrostatic potential 
of D2R from the extracellular side (Figure 2), E952.65 in TM2 (Ballesteros & Weinstein 
numbering scheme18 is shown as superscript) and E181i-1 in ECL2 (at position i-1 relative to 
the conserved C180i engaged in a disulfide bond with C1073.25 in TM3) confer a negative 
character to the channel linking the extracellular environment and the binding site cavity. 
Therefore, we envisaged that a positive charge at the C-terminal position may favour an ionic 
interaction with the extracellular region and enhance binding affinity at D2R. For the central 
position of the tripeptide (AA2, Figure 1a) we selected four different aromatic amino acids 
(Phe(4-F), Phe(3,4-F2), Trp and Tyr) to explore the influence of H-bond donor and acceptor 
groups (e.g. Trp as a non-polar aromatic H-bond donor, Tyr as a polar aromatic H-bond 
donor and acceptor) as well as hydrophobic fluorinated amino acids, which were well 
tolerated in previous heterocycle-peptide hybrid libraries.13 Finally, we incorporated four 
diverse amino acids (e.g. cyclic (Pro), linear and hydrophobic (Nle), positively (Lys) and 
negatively-charged (Glu)) to explore a relatively broad chemical space at the N-terminal 
position of the tripeptide attached to the alkaloid (AA1, Figure 1a). Notably, all peptide 
combinations were prepared with and without an aminohexanoic spacer to assess the 
interaction of the tripeptides at different extracellular regions of D1R and D2R. We limited the 
size of the library to 80 indoloquinolizidine-peptides with 20 different peptide combinations, 
which did not repeat any amino acid and did not contain more than one positive charge. 
Figure 2. Illustration of the molecular electrostatic potential at the extracellular surface of 
D2R. 
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Chemical synthesis. Since there are no reports of indolo[2,3-a]quinolizidines being loaded 
and released from polystyrene (PS) solid supports, we optimised the coupling and cleavage 
conditions of 1 and 2 onto Rink-MBHA-PS as well as on two PS-supported tripeptides (i.e. 
Glu-Trp-Pro-Rink-MBHA-PS and Pro-Tyr-Lys-Rink-MBHA-PS). Couplings using PyBOP 
and HOAt in the presence of DIPEA yielded the corresponding amides in high purities within 
2 h (Table 1). To examine whether 1 and 2 were stable under conventional cleavage 
conditions and there was no epimerization of the C12b of the indolo[2,3-a]quinolizidine 
core,19,20 we treated both diastereoisomers with TFA:H2O:DCM (95:2.5:2.5) and confirmed 
by HPLC that the indolo[2,3-a]quinolizidine core was unaffected after treatment with high 
concentrations of trifluoroacetic acid (TFA) (Figure S1 in Electronic Supporting Information 
(ESI)). 
Table 1. 
After preparing all 20 tripeptides using standard SPPS conditions (DIC and HOBt as an 
additive, Scheme 1), the resulting chemset 4 was split into two aliquots, one of which was 
modified with Fmoc-amino hexanoic acid to render the chemset 5. Carboxylic acids 1 and 2 
were attached to both chemsets 4 and 5 using the above mentioned conditions (Scheme 1). 
The cleavage of the library was performed using optimised conditions for compounds with 
positively-charged C-terminal amino acids (TFA:H2O:DCM, 30:5:65)21 and TFA:H2O:DCM 
(95:2.5:2.5) for the rest of the library. The final 80 indoloquinolizidine-peptides were isolated 
in very high purities (> 90%) after simple solid-phase extraction or semi-preparative RP-
HPLC. All 80 compounds were characterised by HPLC-MS prior to the biological assays 
(Tables S1 and S2 in ESI). 
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Scheme 1. Solid-phase synthesis of a combinatorial library of indoloquinolizidine-
peptides. Reaction conditions: a) Fmoc-AA3-OH, DIC, HOBt, b) piperidine-DMF (2:8), c) 
Fmoc-AA2-OH, DIC, HOBt, d) Fmoc-AA1-OH, DIC, HOBt, e) Fmoc-Ahx-OH, DIC, HOBt, 
f) 1, PyBOP, HOAt, DIPEA, g) TFA:H2O:DCM, h) 2, PyBOP, HOAt, DIPEA. 
 
Binding assays and structure-affinity relationships. The binding affinities of 
indoloquinolizidine-peptides for D1R and D2R were examined by competitive radioligand 
displacement against the D1R antagonist [3H]-SCH 23390 and the D2R antagonist [3H]-YM 
09151-2, respectively, in membrane preparations from sheep striatum. Weak binding was 
observed in compounds containing negatively charged amino acids (i.e. Glu) in the tripeptide 
moiety, whereas binding affinities were significantly increased when a positively charged 
amino acid (e.g. Lys, Amp) was included at the C-terminal position (Figure S2 in ESI). This 
observation confirmed our hypothesis that positively charged residues may enhance binding 
affinity by interacting with the anionic extracellular regions of dopamine receptors. From our 
primary screen we also observed some preference in the stereochemistry of the 
indoloquinolizidine scaffold, especially at D2R. Cis derivatives showed low to moderate 
affinities at D2R while stronger interactions were obtained for the corresponding trans 
derivatives. The incorporation of the aminohexanoic spacer at D2R had variable results: in 
some compounds the spacer slightly improved the affinity at D2R (e.g. 7{3,1,1} vs. 9{3,1,1} 
or 7{3,2,1} vs. 9{3,2,1}), while in some others binding affinities remained unaffected (e.g. 
7{2,4,2} vs. 9{2,4,2} or 7{4,2,1} vs. 9{4,2,1}) (Figure S2 in ESI). 
A group of 10 indoloquinolizidine-peptides with the best binding profiles at D1R and D2R 
(e.g. 9{2,2,2}, 9{2,4,2}, 7{2,1,3}, 9{1,2,3}, 7{2,2,3}, 9{1,3,3}, 7{2,3,3}, 9{2,4,3}, 6{2,4,2}, 
8{2,1,3}) was further examined and their affinity constants (KD) were determined. Most of 
the selected indoloquinolizidine-peptides showed monophasic competition curves at D1R (i.e. 
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no distinction between high and low-affinity states), thus we compared their KD average 
values at D1R. On the other hand, when competition curves at D2R were biphasic, we 
determined both their high-affinity (KD1) and low-affinity (KD2) constants. 
Table 2. 
Notably, compounds consisting of the same tripeptide and trans indoloquinolizidine -
regardless of the presence/absence of aminohexanoic spacer- showed remarkably lower KD 
values at D2R than the corresponding cis derivatives, which corroborates the importance of 
the indoloquinolizidine stereochemistry for the interaction at dopamine receptors. 
Specifically, we compared 9{2,4,2} and 6{2,4,2} as two indoloquinolizidine-peptides with the 
same tripeptide (i.e. Nle-Phe(4F)-Amp) and different indoloquinolizidine configuration (i.e. 
trans for 9{2,4,2} and cis for 6{2,4,2}). As shown in Table 2, the KD1 for 9{2,4,2} at D2R was 
10 times lower than the one for 6{2,4,2}, proving the higher affinity of the trans compound at 
D2R. This observation was also corroborated for the derivatives 7{2,1,3} and 8{2,1,3}, which 
contained the same tripeptide (i.e. Nle-Tyr-Lys). In this case, the trans derivative 7{2,1,3} 
showed a KD1 at D2R around 1.5 times lower than the cis derivative 8{2,1,3}. In addition to 
showing affinities in the submicromolar range at D1R and nanomolar range at D2R, selected 
indoloquinolizidine-peptides showed marginal binding (medium and high micromolar range) 
at other GPCRs in brain striatum (e.g. adenosine A1 and A2A receptors, Table S3 in ESI). We 
selected 9{1,3,3} as a multiple ligand for dopamine receptors with some D2R selectivity, 
showing micromolar affinity at D1R and nanomolar affinity at D2R. Molecules with such 
pharmacological profile are excellent candidates to restore the effects of dopamine depletion 
and enhance motor activation without causing any dysregulation of the trafficking and 
desensitization of D1R, which could lead to undesired dyskinesias.22,23 Furthermore, the 
scale-up synthesis of 9{1,3,3} enabled the isolation of the two trans diasteroisomers that were 
characterised and named as 9a{1,3,3} and 9b{1,3,3} (Figure 3).  
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Figure 3. Chemical structures of isolated trans diasteroisomers of 9{1,3,3}. 
 
 
We measured the high-affinity (KD1) and low-affinity (KD2) constants for 9a{1,3,3} and 
9b{1,3,3} at D1R and D2R in membrane preparations from sheep striatum by competition 
assays, where constant concentrations of D1R and D2R antagonists ([3H]-SCH 23390 and 
[3H]-YM 09151-2, respectively) were co-incubated with increasing concentrations of 
9a{1,3,3} and 9b{1,3,3} (Figure S3 in ESI). Notably, the two diastereoisomers showed 
biphasic competition curves at D1R and D2R, and we determined both their KD1 and 
KD2 constants at the two receptors (Table 3). The different stereochemistry of the two 
indoloquinolizidine-peptides led to significantly higher affinity of 9a{1,3,3} at the D2R low-
affinity state (KD2), whereas no significant differences were detected between the binding 
values of 9a{1,3,3} and 9b{1,3,3} at any of the affinity states of D1R (Table 3). These results 
correlated with our in silico assays at D2R (Figure 4), and allowed us to assign the absolute 
stereochemistry of 9a{1,3,3} as the diastereoisomer with the best molecular fitting at this 
receptor. Altogether, this data confirmed our previous observation that binding at D2R shows 
higher dependency on the stereogenicity of the indoloquinolizidine core, while affinities at 
D1R are not largely affected by the stereochemistry of the indoloquinolizidine structure. 
Table 3. 
Encouraged by the high binding affinity of 9a{1,3,3} at D2R, we examined its behavior at the 
receptor. We assessed whether 9a{1,3,3} could bind allosterically at D2R since 
indoloquinolizidine derivatives have been described as allosteric ligands for dopamine 
receptors.14 We performed dissociation kinetic assays in membranes that were pre-incubated 
with or without 9a{1,3,3} before adding different concentrations of the orthosteric 
radioligand [3H]-YM 09151-2. After 2 h the dissociation was initiated by addition of YM 
09151-2 and we measured the total binding at every time point by rapid filtration and 
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radioactivity counting. As shown in Table 4, the addition of 9a{1,3,3} did not significantly 
alter the Koff of YM 09151-2 at D2R, which suggests that 9a{1,3,3} does not behave as an 
allosteric modulator at D2R. 
Table 4.  
Computational model of D2R in complex with 9a{1,3,3}. In an attempt to get a better 
understanding of the interaction between indoloquinolizidine-peptides and D2R, we 
constructed a three-dimensional model of the complex between 9a{1,3,3} and a homology 
model of D2R. The indoloquinolizidine moiety of the ligand was docked into the orthosteric 
binding pocket of the receptor in such a manner that the protonated NH group of the ring 
formed an ionic interaction with D1143.32 and the indole part formed edge-to-face aromatic-
aromatic interactions with W3866.48 and F3906.52 (Figure 4a). The aminohexanoic spacer 
expanded through a channel located between the extracellular segments of TMs 2, 3 and 7 
towards the extracellular environment, which has been proposed to be part of the ligand 
entry/exit pathway to/from the orthosteric binding site.24 We refined this initial binding mode 
using molecular dynamics (MD) simulations of the ligand-receptor complex (see 
Experimental section). The structures of the ligand-receptor complex computed during MD 
simulations are depicted in Figure 4b. Importantly, the key proposed interactions between the 
indoloquinolizidine moiety of 9a{1,3,3} and the orthosteric binding cavity of the receptor 
remained stable through the simulation time. The tripeptide moiety of 9a{1,3,3} expanded 
towards the extracellular part so that lysine could form an ionic interaction with E952.65 in 
TM2. It is important to note that other initial docking poses in which lysine was placed in 
close proximity to E181i-1 modified its conformation during the simulation time to finally 
accomplish the interaction with E952.65. Furthermore, the aromatic ring of the central position 
of the tripeptide formed aromatic-aromatic interactions with Y4087.35, the fluorine atoms 
formed halogen bonds with N3966.58 and the terminal acetamide group acted as both 
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hydrogen bond donor and acceptor with the backbone C=O and N-H groups of C180i in 
ECL2. 
Figure 4. Molecular dynamics simulations of D2R in complex with 9a{1,3,3}. a) The 
structure of the ligand-receptor complex computed during MD trajectories. 9a{1,3,3} is 
shown in white and the side chains of D2R are shown in green; b) detailed view of the 
interactions between 9a{1,3,3} and D2R. 
 
Functional assays.  We further examined the agonist/antagonist behaviour of 9a{1,3,3} at 
D2R by evaluating the MAPK signal transduction pathway in CHO cells that were transfected 
with D2R. As shown in  
Figure 5, 9a{1,3,3} increased the ERK1/2 phosphorylation in a dose-dependent manner, 
similar to the D2R agonist quinpirole (QP). This result confirms that 9a{1,3,3} behaves as an 
agonist at D2R. Furthermore, combined administration of YM 09151-2, an antagonist of D2R, 
and 9a{1,3,3} did not diminish the capacity of YM 09151-2 to decrease ERK1/2 
phosphorylation, thereby indicating that the 9a{1,3,3} does not behave as a D2R antagonist. 
Figure 5.  Functional characterisation of 9a{1,3,3} at D2R. CHO cells expressing D2R 
were cultured in serum-free medium for 16 h prior to the addition of any ligand. Cells were 
treated (or not) with 1 µM YM 09151-2. After 5 min, 1 µM quinpirole (QP), increasing 
concentrations of compound 9a{1,3,3} or combined 10 µM 9a{1,3,3} with YM 09151-2 were 
incubated for further 5 min and the extent of ERK1/2 phosphorylation was determined as 
described in the Experimental section. Data are represented as means ± SEM of 3 
experiments performed in duplicate. Significant differences were calculated by Student’s t-
test for unpaired samples: * p < 0.05, ** p < 0.01 compared to untreated cells (basal). 
Conclusions. We report the first adaptation of the indolo[2,3-a]quinolizidine privileged 
structure to solid-phase synthesis with the preparation of an 80-member indoloquinolizidine-
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peptide library. In our library we explored peptides around the heterocyclic core to enhance 
the affinity of indoloquinolizidine-peptides at D2R, a receptor that is crucial to re-establish 
activity on dopamine-depleted degenerated GABAergic neurons. Notably, we designed our 
library upon examination of the electrostatic potential at the extracellular regions of D2R, 
which suggested that a positive charge at the C-terminal residue of indoloquinolizidine-
peptides would enhance their affinity at D2R. Binding assays identified a number of 
indoloquinolizidine-peptides with high affinity at both D1R and D2R. Compounds including a 
positively-charged amino acid at the C-terminus showed a significantly higher affinity at both 
receptors, and trans configuration at the indoloquinolizidine core significantly increased the 
selectivity towards D2R. We identified 9a{1,3,3} as a multiple D1/D2 ligand with some D2R 
selectivity -micromolar affinity at D1R and nanomolar affinity at D2R- and studied the 
binding and functional properties at D2R. Molecular dynamics simulations corroborated the 
proposed interactions between the indoloquinolizidine moiety and the orthosteric binding 
cavity as well as an ionic interaction between the C-terminal lysine and the anionic residues 
at the extracellular regions at D2R. Furthermore, functional assays confirmed that 9a{1,3,3} is 
an agonist of D2R. These results validate the application of indoloquinolizidine-peptide 
combinatorial libraries as a platform to fine-tune the pharmacological profile of multiple 
ligands at D1 and D2 dopamine receptors.   
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Experimental section. 
Materials and equipment. All Fmoc-amino acids were purchased from Neosystem 
(Strasbourg, France) and Fmoc-Rink-PS resin was supplied by Calbiochem-Novabiochem 
AG. DIC was obtained from Fluka (Buchs, Switzerland) and HOBt from Albatross Chem, 
Inc. (Montreal, Canada). Solvents for peptide synthesis and RP-HPLC equipment were 
obtained from Scharlau (Barcelona, Spain). Trifluoroacetic acid was supplied by KaliChemie 
(Bad Wimpfen, Germany). Other chemicals of the highest commercially available purity 
were purchased from Aldrich (Milwaukee, WI). All commercial reagents and solvents were 
used as received. Adenosine deaminase (EC 3.5.4.4) was purchased from Roche (Basel, 
Switzerland) and [3H]-R-PIA was supplied by Amersham Biosciences (Buckinghamshire, 
UK). Raclopride, polyethylenimine (PEI), MgCl2, DPCPX, mouse anti-phospho-ERK1/2 
antibody and rabbit anti-ERK1/2 antibody were purchased from Sigma (St Louis, MO). 
Rabbit anti-P-Ser473Akt antibody was purchased from SAB Signalway (Pearland, U.S.A.). 
ZM241385 and SCH 23390 were supplied by Tocris Biosciences (Avonmouth, UK). [3H]-
SCH 23390, [3H]-YM 09151-2 and [3H]-ZM 241385 were supplied by Perkin Elmer 
(Wellesley, MA, USA). Ecoscint H scintillation cocktail was purchased from National 
Diagnostics (Atlanta, GA, USA). Bradford assay kit was purchased from Bio-Rad (Munich, 
Germany). All other supplements were purchased from Invitrogen (Paisley, UK). Analytical 
RP-HPLC-MS was performed using 2795 Waters (Milford, MA) Alliance with a Micromass 
ZQ Mass Spectrometer and a 996 PDA detector. Semi-preparative RP-HPLC was performed 
on a 2767 Waters chromatography system with a Micromass ZQ Mass Spectrometer. 
Multiple sample evaporation was carried out in a Discovery SpeedVac ThermoSavant 
(Waltham, MA). Radioligand binding experiments were performed using a Brandel 
(Gaithersburg, MD) cell harvester and a Packard 1600 TRI-CARB scintillation counter with 
an efficiency of 62%. Fitting data binding program GraFit was obtained from Erithacus 
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Software (Surrey, UK). For ERK1/2
 
phosphorylation determination, the Odyssey infrared 
scanner (LI-COR Biosciences, Lincoln, Nebraska, USA) was used. Band densities were 
quantified using the scanner software and exported to Excel (Microsoft, Redmond, WA, US). 
Solid-phase general procedures. Peptide syntheses were performed manually in 
polypropylene syringes, each fitted with a polyethylene porous disk. Solvents and soluble 
reagents were removed by filtration. Washings between deprotection, coupling and 
subsequent deprotection steps were carried out with DMF (5 × 1 min) and DCM (5 × 1 min) 
using 10 mL of solvent/g of resin each time.  
Coupling using DIC and HOBt or HOAt. Carboxylic acids (3 equiv) were coupled using 
DIC (3 equiv) as coupling reagent and HOBt (3 equiv) or HOAt (3 equiv) as additives in 
DCM-DMF (1:1) for 2 h at r.t. After each coupling, the resin was washed with DMF (5 × 1 
min) and DCM (5 × 1 min). Reaction completion was checked by means of the Kaiser or 
chloranil tests. 
Fmoc group removal. (i) DMF (5 × 1 min); (ii) piperidine-DMF (2:8) (1 × 1 min + 2 × 15 
min); (iii) DMF (5 × 1 min). 
Cleavage of the resins. The resins were treated with solutions of TFA-H2O-DCM 
(95:2.5:2.5) or TFA-H2O-DCM (30:5:65) and orbitally shaken for 1 h at r.t. Filtrates were 
collected, washed with TFA (2 × 1 min) and DCM (3 × 1 min) and evaporated under vacuum. 
Purification of the library. A) Solid-phase extraction purification. Crudes were dissolved 
in a mixture of DCM-MeOH (1:1, v/v) and loaded onto a SCX-2 column previously 
conditioned with a mixture of DCM-MeOH (1:1, v/v). Impurities were eluted with DCM-
MeOH and the products were liberated from the column with a solution of NH3 in MeOH. 
B) RP-HPLC-MS purification. A small portion of the library was purified by semi-
preparative RP-HPLC-MS using a reversed-phase Symmetry C18 (30 × 100 mm2, 5µm) 
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column. Elution system: A: H2O/HCOOH, 99.9:0.1; B: CH3CN/HCOOH, 99.9:0.1. Flow 
rate: 25 mL·min-1. Purification gradient: 0-50% or 0-55% B over 30 min. 
Synthesis of the indoloquinolizidine-peptide library. The 80-member library synthesis was 
carried out in a MiniBlock reactor. For each of the 20 chemsets, 400 mg of Fmoc-Rink-
MBHA resin (0.7 mmol·g-1) were swollen with DCM (1 × 1 min, 2 × 10 min) and DMF (5 × 
1 min, 1 × 15 min) before use. After washing, the Fmoc group was removed and the 3 amino 
acids were coupled as above mentioned. At this point, resins were split into two equal 
aliquots and Fmoc-Ahx-OH was coupled to half the library using DIC and HOBt. Chemset 
resins 4 and 5 were thoroughly washed and divided again in two parts, obtaining at that point 
80 syringes with 100 mg of resin each. A solution of 1 (1.6 g, 7 mmol, 2.5 equiv), PyBOP 
(3.6 g, 7 mmol, 2.5 equiv) and HOAt (1 g, 7 mmol, 2.5 equiv) in 40 mL of DMF was 
prepared. Similarly, a solution of 2 (1.2 g, 7 mmol, 2.5 equiv), PyBOP (2.8 g, 5.6 mmol, 2 
equiv) and HOAt (0.8 g, 5.6 mmol, 2 equiv) in 40 mL of DMF was prepared. For each of the 
acids, 1 mL of the aforementioned solution was added to each of the 40 chemset resins 
together with DIPEA (63 µL, 0.35 mmol, 5 equiv), and the 80 resins were stirred for 2 h at 
r.t. Cleavages were performed as described above. Multiple evaporation in the ThermoSavant 
Discovery SpeedVac rendered the crude mixtures that were further purified as above 
mentioned. 
Scale-up of 9{1,3,3}. Fmoc-Rink-MBHA resin (0.2 g, 0.112 mmol, 0.56 mmol/g) was 
swollen in DCM (1 × 1 min, 2 × 10 min) before used and treated with piperidine to remove 
the Fmoc group as previously described. Amino acids (3 equiv) were coupled using DIC (3 
equiv) and HOBt (3 equiv) in DCM:DMF (1:1) for 2 h at r.t. or using PyBOP (3 equiv), 
HOBt (3 equiv) and DIPEA (6 equiv) for 1-2 h. After each coupling the resin was washed 
with DMF (5 × 1 min) and DCM (5 × 1 min). Reaction completion was monitored by Kaiser 
or chloranil tests. For the coupling of the indolo[2,3-a]quinolizidine structure, we used the 
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racemic mixture 2 (Figure 1a). After coupling, the resulting mixture was cleaved as indicated 
above and purified by semi-preparative RP-HPLC-MS. The two trans diasteroisomers 
(9a{1,3,3} and 9b{1,3,3}) were isolated and used separately in biological assays. Full 
characterisation data for compounds 9a{1,3,3} and 9b{1,3,3} is included in the Electronic 
Supporting Information (ESI). 
Radioligand binding experiments: general procedure. Membrane suspensions from sheep 
striatum were obtained following methods described previously.25,26 Tissue was disrupted 
with a Polytron homogenizer (PTA 20 TS rotor, setting 3; Kinematica, Basel, Switzerland) 
for three 5 s-periods in 10 volumes of 50 mM Tris–HCl buffer, pH 7.4 containing a 
proteinase inhibitor cocktail (Sigma, St. Louis, MO, USA). Cell debris were eliminated and 
membranes were obtained by centrifugation at 105,000 g (40 min, 4 ºC), and the pellet was 
resuspended and recentrifuged under the same conditions. The pellet was stored at -80 ºC and 
was washed once more as described above and resuspended in 50 mM Tris–HCl buffer for 
immediate use. Protein was quantified by the bicinchoninic acid method (Pierce Chemical 
Co., Rockford, IL, USA) using bovine serum albumin dilutions as standard. 
Radioligand binding assays of membrane suspensions (0.2-0.3 mg protein•mL-1) were carried 
out at 25ºC in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl2 and 0.2-2 U/mL 
adenosine deaminase (ADA) with the indicated concentrations (see conditions used for each 
receptor below). After radioligand incubation, free and membrane-bound ligand were 
separated by rapid filtration of 500 µL aliquots in a cell harvester through Whatman GF/C 
filters embedded in polyethylenimine (0.3%) that were subsequently washed for 5 s with 5 
mL of ice-cold Tris–HCl buffer.25 Nonspecific binding was determined with non-labeled 
ligands at the concentration indicated below. In all cases, the filters were incubated with 10 
mL Ecoscint H scintillation cocktail overnight at r.t. Radioactivity counts in the vials were 
determined using a scintillation counter. 
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Library screening. Initial binding experiments of the whole library were performed at a 
concentration of 50 µM for all compounds. 
D1R. Membranes were incubated with 2 nM [3H]-SCH 23390 (85 Ci mmol-1) in 50 mM Tris-
HCl buffer (pH 7.4) containing 10 mM MgCl2 for 1.5 h in the presence or in the absence of 
the tested compounds. Nonspecific binding was measured in the presence of 50 µM SCH 
23390. 
D2R. Membranes were incubated with 2 nM [3H]-YM 09151-2 (85.5 Ci mmol-1) in 50 mM 
Tris-HCl buffer (pH 7.4) containing 10 mM MgCl2 for 2 h in the presence or in the absence 
of the tested compounds. Nonspecific binding was measured in the presence of 50 µM 
raclopride. 
A1R. Membranes were incubated with 1 nM [3H]-R-PIA (30.5 Ci mmol-1) in 50 mM Tris-HCl 
buffer (pH 7.4) containing 10 mM MgCl2 and 0.2 U mL-1 ADA for 2 h in the presence or in 
the absence of the tested compounds. Nonspecific binding was measured in the presence of 
50 µM DPCPX. 
A2AR. Membranes were incubated with 1 nM [3H]-ZM 241385 (27.4 Ci mmol-1) in 50 mM 
Tris-HCl buffer (pH 7.4) containing 10 mM MgCl2 and 2 U mL-1 ADA for 1.5 h in the 
presence or in the absence of the tested compounds. Nonspecific binding was measured in the 
presence of 50 µM ZM-241385. 
KD determination. Competition experiments were performed by incubating membranes 
under the same conditions as described above, in the absence or presence of increasing 
concentrations of the 10 selected indoloquinolizidine–peptide hybrids ((9{2,2,2}, 9{2,4,2}, 
7{2,1,3}, 9{1,2,3}, 7{2,2,3}, 9{1,3,3}, 7{2,3,3}, 9{2,4,3}, 6{2,4,2}, 8{2,1,3}) for D1R and D2R. 
Nonspecific binding was determined as previously outlined. Radioligand displacement curves 
were analyzed by nonlinear regression using the commercial program GraFit (Erithacus 
Software, Surrey, UK) by fitting the total binding data to the displacement models with one 
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or two affinity sites.27,28 Goodness of fit was tested following the reduced χ2 value given by 
the nonlinear regression program in GraFit. A modified F test was used to analyze whether 
the fit to the two-site model significantly improved on the fit to the one-site model, and p < 
0.05 was taken as a criterion of significance; when no significant improvement over the one-
site model was detected, the p values were > 0.30. 
Biological characterisation of 9a{1,3,3} and 9b{1,3,3}. For competition assays of 
compounds 9a{1,3,3} and 9b{1,3,3} membrane suspensions (0.2–0.5 mg protein/mL) were 
prepared as previously described and incubated 2 h at 25ºC in 50 mM Tris–HCl buffer, pH 
7.4, containing 10 mM MgCl2  with the indicated free concentration of the D1 receptor 
antagonist [3H]-SCH 23390 or with the indicated free concentration of the D2 receptor 
antagonist [3H]-YM 09151-2 and increasing concentrations of 9a{1,3,3} or 9b{1,3,3} 
(triplicates of 9 different concentrations from 1 nM to 50 µM). Nonspecific binding was 
determined in the presence of 50 µM SCH 23390 or 50 µM raclopride, and confirmed that 
the value was the same as calculated by extrapolation of the competition curves.  
For dissociation kinetic assays, sheep brain striatum membranes (0.2 mg of protein/mL) were 
incubated for 1 h at 25 °C with or without 3 µM of 9a{1,3,3}  in Tris-HCl buffer (50 mM, pH 
7.4) containing 10 mM MgCl2 before adding 1 nM [3H]-YM 09151-2. After 2 h the 
dissociation was initiated by the addition of 10 µM YM 09151-2. At the indicated time 
interval total binding was measured by rapid filtration and determination of radioactivity 
counts as indicated above. Nonspecific binding was measured after 90 min incubation in the 
presence of 10 µM YM 09151-2. 
Cell culture and transient transfection. CHO cells, grown as previously described,26,29 
were transiently transfected with D2R cDNA by Lipofectamine (Invitrogen) following the 
instructions of the supplier. Cells were used 48 h after transfection. 
ERK1/2 phosphorylation assays. Transfected CHO cells were cultured in serum-free 
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medium for 16 h before the addition of the indicated concentration of ligands for the 
indicated time. Cells and slices were lysed in ice-cold lysis buffer and ERK1/2 
phosphorylation was determined as indicated elsewhere.29 
Molecular modeling. Modeller v9.1030 was used to build a homology model of human D2R 
(Uniprot code P14416) using the crystal structure of the dopamine D3R (PDB code 3PBL)31 
as template. 9a{1,3,3} was docked by interactive computer graphics, using PyMol,32 into the 
receptor model with its protonated NH group of the ring interacting with D1143.32. This 
structure was placed in a rectangular box containing a lipid bilayer (182 molecules of POPC) 
with explicit solvent (14335 water molecules) and a 0.15 M concentration of Na+ and Cl- 
ions. This initial complex was energy minimized and subsequently subjected to a 10 ns MD 
equilibration, with positional restraints on protein coordinates, to remove possible voids 
present in protein/lipids or proteins/water interfaces. These restraints were released, and 200 
ns MD trajectories were produced at constant pressure and temperature, using the particle 
mesh Ewald method to evaluate electrostatic interactions. Computer simulations were 
performed with the GROMACS 4.5.3 simulation package,33 using the AMBER99SB force 
field34 as implemented in GROMACS, Berger parameters for POPC lipids,35 and the general 
Amber force field (GAFF)36 and HF/6-31G*-derived RESP atomic charges for the ligand. 
This procedure has been previously validated.37 The molecular electrostatic potential on the 
extracellular surface was calculated and displayed with the program VASCo 1.02.38 
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Table 1. Optimisation of the coupling of indolo[2,3-a]quinolizidine carboxylic acids 1 and 2 
to solid support. 
Acid Supported amine Coupling conditions Reaction time (h) Purity* 
1 Rink-MBHA-PS DIC, HOAt 16 39 
1 Rink-MBHA-PS PyBOP, HOAt, DIPEA 2 90 
2 Rink-MBHA-PS DIC, HOAt 16 35 
2 Rink-MBHA-PS PyBOP, HOAt, DIPEA 2 92 
1 Glu-Trp-Pro-PS’ PyBOP, HOAt, DIPEA 2 95 
2 Glu-Trp-Pro-PS’ PyBOP, HOAt, DIPEA 2 92 
1 Pro-Tyr-Lys-PS’ PyBOP, HOAt, DIPEA 2 93 
2 Pro-Tyr-Lys-PS’ PyBOP, HOAt, DIPEA 2 95 
* Determined by HPLC monitoring UV-absorbance at 220 nm; PS: polystyrene; PS’:Rink-
MBHA-PS. 
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Table 2. KD values (µM) of selected indoloquinolizidine-peptides at D1R and D2R.ǂ  
Code Description D1R 
D2R 
KD1 KD2 
6{2,4,2} cis{Nle-Phe(4F)-Amp} 27±2 5.0±0.5 -- 
8{2,1,3} cis-spacer{Nle-Tyr-Lys} 38±3 6.3±0.7 -- 
9{1,2,3} trans-spacer{Pro-Trp-Lys} 2.9±0.7 0.24±0.09 7±2 
9{1,3,3} trans-spacer{Pro-Phe(3,4-F2)-Lys} 15±1 0.28±0.08 9±3 
7{2,1,3} trans{Nle-Tyr-Lys} 1.2±0.1 4.7±0.7 -- 
9{2,2,2} trans-spacer{Nle-Trp-Amp} 3.4±0.3 0.6±0.2 20±10 
7{2,2,3} trans{Nle-Trp-Lys} 1.9±0.4 0.9±0.2 16±4 
7{2,3,3} trans{Nle-Phe(3,4-F2)-Lys} 1.3±0.2 0.19±0.06 8±3 
9{2,4,2} trans-spacer{Nle-Phe(4F)-Amp} 4.0±1.0 0.5±0.2 13±4 
9{2,4,3} trans-spacer{Nle-Phe(4F)-Lys} 3.3±0.7 2.0±1.0 -- 
ǂ Data are represented as means ± SD of three different experiments performed in triplicate. 
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Table 3. KD (µM) values of 9a{1,3,3} and 9b{1,3,3} at D1R and D2R.ǂ 
 BE1 (pmol/mg prot) KD1 (µM) BE2 (pmol/mg prot) KD2 (µM) 
D1R 
9a{1,3,3}  0.13±0.02 1.5±0.9 0.35±0.06 24±6 
9b{1,3,3}  0.14±0.05 1.6±0.8 0.24±0.05 30±7 
D2R 
9a{1,3,3}  0.04±0.02 0.2±0.1 0.12±0.02 4±1 
9b{1,3,3} 0.06±0.02 0.4±0.2 0.12±0.02 14±5* 
ǂ Data are represented as means ± SD of three different experiments performed in triplicate.  
* Statistical significance (p < 0.05) was calculated by a Student’s t-test compared to the KD2 
value of 9a{1,3,3}.  
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Table 4. Dissociation assay of [3H]-YM 09151-2 at D2R in the presence of 9a{1,3,3}. 
 BE (pmol/mg prot) Koff (min-1) 
[3H]-YM 09151-2 0.21±0.01 0.018±0.002 
[3H]-YM 09151-2+9a{1,3,3} 0.13±0.02 0.018±0.004 
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Highlights 
 
A Solid-Phase Combinatorial Approach for Indoloquinolizidine-Peptides with High 
Affinity at D1 and D2 Dopamine Receptors 
 
• Indolo[2,3-a]quinolizidines were used for the first time in solid-phase synthesis.  
• A positively charged C-terminus in indoloquinolizidine-peptides enhances their affinity at 
D2R.  
• Trans configuration of the indoloquinolizidine increases selectivity towards D2R.  
• 9a{1,3,3} is a D1/D2 ligand with submicromolar affinity at D1R, and nanomolar affinity 
and agonist activity at D2R.  
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1.  Stability assays for indolo[2,3-a]quinolizidine carboxylic acids 1 and 2. 
 
 
 
Figure S1. HPLC characterisation of acids 1 and 2 after treatment with TFA:H2O:DCM 
(95:2.5:2.5). a) HPLC of acid 1; b) HPLC of acid 2; c) co-elution of acids 1 and 2. HPLC 
conditions: Symmetry C18 column (4.6 × 75 mm, 5µm), 0-60% B in 15 min, (A:H2O-TFA 
(99.9:0.1), B: ACN-TFA (99.9:0.1)), flow: 1 mL min-1, detection at 220 nm. 
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2. Characterisation data for the whole library. 
Table S1. HPLC purities of the whole library of indoloquinolizidine-peptides.  
compound mg purity (sist1%-sist2%)* compound mg purity (sist1%-sist2%)* 
6{1,1,3} 3.7  94%-96% 7{1,1,3} 5.7  94%-92% 
6{1,2,3} 10.8  97%-95% 7{1,2,3} 6.9  98%-97% 
6{1,3,3} 4.1  95%-95% 7{1,3,3} 4.3  98%-96% 
6{1,4,3} 4.0  92%-90% 7{1,4,3} 4.8  98%-92% 
6{2,1,2} 0.8  97%-93% 7{2,1,2} 35.4  91%-80% 
6{2,1,3} 7.7  94%-96% 7{2,1,3} 6.3  93%-95% 
6{2,2,2} 2.7  99%-93% 7{2,2,2} 6.0  94%-96% 
6{2,2,3} 5.3  97%-95% 7{2,2,3} 8.6  99%-98% 
6{2,3,2} 0.6  93%-95% 7{2,3,2} 0.6  97%-95% 
6{2,3,3} 7.2  95%-89% 7{2,3,3} 5.5  94%-91% 
6{2,4,2} 0.5  88%-90% 7{2,4,2} 0.8   90%-90% 
6{2,4,3} 6.9  90%-88% 7{2,4,3} 9.8  91%-85% 
6{3,1,1} 15.7  91%-93% 7{3,1,1} 78.0  99%-94% 
6{3,2,1} 26.2  97%-95% 7{3,2,1} 30.7  94%-91% 
6{3,3,1} 17.4  95%-95% 7{3,3,1} 17.6  99%-98% 
6{3,4,1} 22.1  87%-83% 7{3,4,1} 7.4  98%-96% 
6{4,1,1} 54.5. 92%-89% 7{4,1,1} 6.6  90%-90% 
6{4,2,1} 44.9  91%-88% 7{4,2,1} 10.3  92%-91% 
6{4,3,1} 54.9  96%-92% 7{4,3,1} 64.8 96%-93% 
6{4,4,1} 53.9  90%-92% 7{4,4,1} 17.6  92%-89% 
8{1,1,3} 2.7  89%-90% 9{1,1,3} 1.2  99%-98% 
8{1,2,3} 4.7  93%-94% 9{1,2,3} 7.3  99%-97% 
8{1,3,3} 2.5  91%-90% 9{1,3,3} 5.3  93%-91% 
8{1,4,3} 22.0  85%-88% 9{1,4,3} 3.5  93%-98% 
8{2,1,2} 0.8  82%-85% 9{2,1,2} 1.0  84%-89% 
8{2,1,3} 4.6  85%-87% 9{2,1,3} 5.5  91%-94% 
8{2,2,2} 0.4  92%-98% 9{2,2,2} 1.2  96%-93% 
8{2,2,3} 3.4  83%-86% 9{2,2,3} 2.4  85%-92% 
8{2,3,2} 0.5 80%-88% 9{2,3,2} 5.9  85%-86% 
8{2,3,3} 0.7  99%-98% 9{2,3,3} 2.1  99%-99% 
8{2,4,2} 1.0  92%-90% 9{2,4,2} 0.6  81%-83% 
8{2,4,3} 1.5  96%-98% 9{2,4,3} 4.0  83%-80% 
8{3,1,1} 13.2  80%-88% 9{3,1,1} 15.1  80%-89% 
8{3,2,1} 8.0  85%-95% 9{3,2,1} 16.8  93%-94% 
8{3,3,1} 6.6  91%-92% 9{3,3,1} 7.3  99%-99% 
8{3,4,1} 5.0  91%-90% 9{3,4,1} 9.7  95%-86% 
8{4,1,1} 4.3  98%-99% 9{4,1,1} 0.7   99%-99% 
8{4,2,1} 68.4. 79%-94% 9{4,2,1} 42.9  89%-87% 
8{4,3,1} 1.9  99%-99% 9{4,3,1} 2.6  99%-83% 
8{4,4,1} 1.7  99%-99% 9{4,4,1} 8.1  99%-99% 
*Sist1: HPLC conditions: Symmetry C18 column (4.6 × 75 mm, 5µm), 0-60% B in 10 min, (A: H2O-TFA 
(99.9:0.1), B: ACN-TFA (99.9:0.1)), flow: 1 mL min-1, detection at 220 nm.*Sist2: HPLC conditions: Symmetry 
C18 column (4.6 × 75 mm, 5µm), 0-60% B in 10 min, (A: H2O-HCOOH (99.9:0.1), B: ACN-HCOOH 
(99.93:0.07)), flow: 1 mL min-1, detection at 220 nm. 
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Table S2. HPLC data, MS data and chemical structures for the whole library of 
indoloquinolizidine-peptides. 
Code Chemical structure tR HPLC1 (min) Mcalc. 
Mexp. 
[M+H+] 
6{3,1,1} HN NH N
O
O
O NH2
OH
NH2
N
H
N
OH
 
5.93 657.4 658.4 
6{4,1,1} HN N
H
N
O
O
OH
O NH2
OH
O
N
H
N
OH
 
6.41 658.3 659.4 
6{3,2,1} HN N
H
N
O
O
O NH2
NH2
NH
N
H
N
OH
 
6.79 680.4 681.5 
6{4,2,1} HN
N
H
N
O
O
OH
O NH2
O
NH
N
H
N
OH
 
7.30 681.3 682.4 
6{3,3,1} HN NH N
O
O
O NH2
F
NH2
F
N
H
N
OH
 
6.89 677.4 678.5 
6{4,3,1} HN
N
H
N
O
O
OH
O NH2
F
O
F
N
H
N
OH
 
7.47 678.3 679.4 
6{3,4,1} HN NH N
O
O
O NH2
F
NH2
N
H
N
OH
 
6.73 659.4 660.4 
6{4,4,1} HN N
H
N
O
O
OH
O NH2
F
O
N
H
N
OH
 
7.29 660.3 661.4 
6{2,1,1} HN N
H
N
O
O
O NH2
OH
NH2
N
H
N
OH
 
6.36 
6.64 657.4 658.4 
6{2,2,1} HN
N
H
N
O
O
O NH2
NH NH2
N
H
N
OH
 
7.00 
7.22 680.4 681.4 
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6{2,3,1} HN
N
H
N
O
O
O NH2
F
NH2
F
N
H
N
OH
 
7.20 
7.43 677.4 678.4 
6{2,4,1} HN
N
H
N
O
O
O NH2
F
NH2
N
H
N
OH
 
7.02 
7.26 659.4 660.4 
6{1,1,3} NH HN
O
O
OH
N
NH2
O
NH2
N
H
N O
H
 
5.54 
5.82 657.4 658.5 
6{2,1,3} NH HN
O
O
OH
H
N
NH2
O
NH2
N
H
N
OH
 
6.19 
6.52 673.4 674.5 
6{1,2,3} N
H
H
N
O
O
N
NH2
O
NH2
NH
N
H
N O
H
 
6.34 
6.59 680.4 681.5 
6{2,2,3} N
H
H
N
O
O
H
N
NH2
O
NH2
NH
N
H
N
OH
 
6.92 
7.20 696.4 697.5 
6{1,3,3} NH HN
O
O
F
N
NH2
O
NH2
F
N
H
N O
H
 
6.65 
6.85 677.4 678.4 
6{2,3,3} NH HN
O
O
F
H
N
NH2
O
NH2
F
N
H
N
OH
 
7.18 
7.44 693.4 694.4 
6{1,4,3} NH HN
O
O
F
N
NH2
O
NH2
N
H
N O
H
 
6.46 
6.66 659.4 660.4 
6{2,4,3} NH HN
O
O
F
H
N
NH2
O
NH2
N
H
N
OH
 
7.00 
7.27 675.4 676.5 
8{3,1,1} HN NH N
O
O
O NH2
OH
NH2
N
H
O
O
NH
N
H
 
6.12 770.5 771.5 
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8{4,1,1} HN N
H
N
O
O
OH
O NH2
OH
O
N
H
O
O
NH
N
H
 
6.62 771.4 772.5 
8{3,2,1} HN N
H
N
O
O
O NH2
NH2
NH
N
H
O
O
NH
N
H
 
6.78 793.5 794.5 
8{4,2,1} HN
N
H
N
O
O
OH
O NH2
O
NH
N
H
O
O
NH
N
H
 
7.39 794.4 795.5 
8{3,3,1} HN N
H
N
O
O
O NH2
F
NH2
F
N
H
O
O
NH
N
H
 
6.85 790.4 791.5 
8{4,3,1} HN
N
H
N
O
O
OH
O NH2
F
O
F
N
H
O
O
NH
N
H
 
7.51 791.4 792.5 
8{3,4,1} HN NH N
O
O
O NH2
F
NH2
N
H
O
O
NH
N
H
 
6.72 772.4 773.6 
8{4,4,1} HN N
H
N
O
O
OH
O NH2
F
O
N
H
O
O
NH
N
H
 
7.33 773.4 774.5 
8{2,1,1} HN N
H
N
O
O
O NH2
OH
NH2
N
H
O
O
NH
N
H
 
6.84 770.5 771.5 
8{2,2,1} HN
N
H
N
O
O
O NH2
NH NH2
N
H
O
O
NH
N
H
 
7.40 793.5 794.6 
8{2,3,1} HN
N
H
N
O
O
O NH2
F
NH2
F
N
H
O
O
NH
N
H
 
7.71 790.4 791.5 
8{2,4,1} HN N
H
N
O
O
O NH2
F
NH2
N
H
O
O
NH
N
H
 
7.52 772.4 773.5 
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8{1,1,3} 
N
H
H
N
O
O
OH
N
NH2
O
NH2
NH
O
O
NH
N
H
 
6.31 770.5 771.5 
8{2,1,3} NH HN
O
O
OH
H
N
NH2
O
NH2
N
H
O
O
NH
N
H
 
6.84 786.5 787.5 
8{1,2,3} 
N
H
H
N
O
O
N
NH2
O
NH2
NH
NH
O
O
NH
N
H
 
7.02 793.5 794.5 
8{2,2,3} N
H
H
N
O
O
H
N
NH2
O
NH2
NH
N
H
O
O
NH
N
H
 
7.47 809.5 810.5 
8{1,3,3} 
N
H
H
N
O
O
F
N
NH2
O
NH2
FNH
O
O
NH
N
H
 
7.21 790.4 791.5 
8{2,3,3} NH HN
O
O
F
H
N
NH2
O
NH2
F
N
H
O
O
NH
N
H
 
7.77 806.5 807.5 
8{1,4,3} 
N
H
H
N
O
O
F
N
NH2
O
NH2
NH
O
O
NH
N
H
 
7.02 772.4 773.6 
8{2,4,3} NH HN
O
O
F
H
N
NH2
O
NH2
N
H
O
O
NH
N
H
 
7.59 788.5 789.5 
7{3,1,1} HN NH N
O
O
O NH2
OH
NH2
N
H
N
OH
 
5.84 657.4 658.4 
7{4,1,1} HN N
H
N
O
O
OH
O NH2
OH
O
N
H
N
OH
 
6.33 658.3 659.4 
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7{3,2,1} HN N
H
N
O
O
O NH2
NH2
NH
N
H
N
OH
 
6.72 680.4 681.4 
7{4,2,1} HN
N
H
N
O
O
OH
O NH2
O
NH
N
H
N
OH
 
7.23 681.3 682.4 
7{3,3,1} HN NH N
O
O
O NH2
F
NH2
F
N
H
N
OH
 
6.78 677.4 678.4 
7{4,3,1} HN
N
H
N
O
O
OH
O NH2
F
O
F
N
H
N
OH
 
7.38 678.3 679.4 
7{3,4,1} HN NH N
O
O
O NH2
F
NH2
N
H
N
OH
 
6.63 659.4 660.4 
7{4,4,1} HN N
H
N
O
O
OH
O NH2
F
O
N
H
N
OH
 
7.15 660.3 661.4 
7{2,1,1} HN N
H
N
O
O
O NH2
OH
NH2
N
H
N
OH
 
6.46 
6.57 657.4 658.4 
7{2,2,1} HN
N
H
N
O
O
O NH2
NH NH2
N
H
N
OH
 
7.01 680.4 681.4 
7{2,3,1} HN
N
H
N
O
O
O NH2
F
NH2
F
N
H
N
OH
 
7.30 
7.33 677.4 678.4 
7{2,4,1} HN N
H
N
O
O
O NH2
F
NH2
N
H
N
OH
 
7.11 659.4 660.4 
7{1,1,3} NH HN
O
O
OH
N
NH2
O
NH2
N
H
N O
H
 
5.85 657.4 658.5 
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7{2,1,3} NH HN
O
O
OH
H
N
NH2
O
NH2
N
H
N
OH
 
6.43 673.4 674.5 
7{1,2,3} N
H
H
N
O
O
N
NH2
O
NH2
NH
N
H
N O
H
 
6.58 
6.61 680.4 681.5 
7{2,2,3} N
H
H
N
O
O
H
N
NH2
O
NH2
NH
N
H
N
OH
 
7.13 696.4 697.5 
7{1,3,3} NH HN
O
O
F
N
NH2
O
NH2
F
N
H
N O
H
 
6.77 677.4 678.4 
7{2,3,3} NH HN
O
O
F
H
N
NH2
O
NH2
F
N
H
N
OH
 
7.40 
7.44 693.4 694.4 
7{1,4,3} NH HN
O
O
F
N
NH2
O
NH2
N
H
N O
H
 
6.55 659.4 660.4 
7{2,4,3} NH HN
O
O
F
H
N
NH2
O
NH2
N
H
N
OH
 
7.17 675.4 676.5 
9{3,1,1} HN NH N
O
O
O NH2
OH
NH2
N
H
O
O
NH
N
H
 
6.02 770.5 771.5 
9{4,1,1} HN N
H
N
O
O
OH
O NH2
OH
O
N
H
O
O
NH
N
H
 
6.43 771.4 772.5 
9{3,2,1} HN N
H
N
O
O
O NH2
NH2
NH
N
H
O
O
NH
N
H
 
6.69 793.5 794.5 
9{4,2,1} HN
N
H
N
O
O
OH
O NH2
O
NH
N
H
O
O
NH
N
H
 
7.19 794.4 795.5 
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9{3,3,1} HN N
H
N
O
O
O NH2
F
NH2
F
N
H
O
O
NH
N
H
 
6.71 790.4 791.5 
9{4,3,1} HN
N
H
N
O
O
OH
O NH2
F
O
F
N
H
O
O
NH
N
H
 
7.26 791.4 792.4 
9{3,4,1} HN NH N
O
O
O NH2
F
NH2
N
H
O
O
NH
N
H
 
6.59 772.4 773.6 
9{4,4,1} HN N
H
N
O
O
OH
O NH2
F
O
N
H
O
O
NH
N
H
 
7.16 773.4 774.4 
9{2,1,1} HN N
H
N
O
O
O NH2
OH
NH2
N
H
O
O
NH
N
H
 
6.61 770.5 771.5 
9{2,2,1} HN
N
H
N
O
O
O NH2
NH NH2
N
H
O
O
NH
N
H
 
6.15 793.5 794.5 
9{2,3,1} HN
N
H
N
O
O
O NH2
F
NH2
F
N
H
O
O
NH
N
H
 
6.50 790.4 791.5 
9{2,4,1} HN N
H
N
O
O
O NH2
F
NH2
N
H
O
O
NH
N
H
 
7.23 772.4 773.5 
9{1,1,3} 
N
H
H
N
O
O
OH
N
NH2
O
NH2
NH
O
O
NH
N
H
 
6.04 770.5 771.5 
9{2,1,3} NH HN
O
O
OH
H
N
NH2
O
NH2
N
H
O
O
NH
N
H
 
6.65 786.5 787.5 
9{1,2,3} 
N
H
H
N
O
O
N
NH2
O
NH2
NH
NH
O
O
NH
N
H
 
6.82 793.5 794.5 
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9{2,2,3} N
H
H
N
O
O
H
N
NH2
O
NH2
NH
N
H
O
O
NH
N
H
 
7.30 809.5 810.5 
9{1,3,3} 
N
H
H
N
O
O
F
N
NH2
O
NH2
FNH
O
O
NH
N
H
 
6.99 790.4 791.5 
9{2,3,3} NH HN
O
O
F
H
N
NH2
O
NH2
F
N
H
O
O
NH
N
H
 
7.62 806.5 807.5 
9{1,4,3} 
N
H
H
N
O
O
F
N
NH2
O
NH2
NH
O
O
NH
N
H
 
6.82 772.4 773.5 
9{2,4,3} NH HN
O
O
F
H
N
NH2
O
NH2
N
H
O
O
NH
N
H
 
7.36 788.5 789.5 
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3. High-throughput binding screening of the whole library at D1R and D2R. 
 
 
 
Figure S2. High-throughput binding screening of indoloquinolizidine-peptides at D1R 
and D2R. Specific binding at D1R (a), (b) and D2R (c), (d) as percentage of radioligand 
binding in the absence of competing ligand was measured as indicated in the Experimental 
Section. Highlighted in orange 10 compounds selected for the secondary screening. Left bars: 
control of radioligand binding without competing ligand; SKF & SCH: D1R specific ligands; 
QP, PPHT & Raclo: D2R specific ligands; others: radioligand specific binding in the presence 
of 50 µM of the corresponding indoloquinolizidine-peptides. Radioligands used: a, b) [3H]-
SCH 23390, c, d) [3H]-YM 09151-2. Data are represented as means ± SD from a 
representative experiment (n=3) performed in triplicate. C: Control, PPHT: 2-(N-phenethyl-
N-propyl)amino-5-hydroxytetralin, QP: quinpirole, Raclo: raclopride, SCH: SCH 23390; 
SKF: SKF-38393. 
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4.  Screening of selected indoloquinolizidine-peptides at A1 and A2A adenosine receptors. 
Table S3. KD (µM) values of selected indoloquinolizidine-peptides at A1R and A2AR.  
 A1R A2AR 
6{2,4,2} 12±1 14±4 
8{2,1,3} > 100 16±2 
9{1,2,3} > 100 44±9 
9{1,3,3} > 100 37±5 
7{2,1,3} > 100 60±30 
9{2,2,2} > 100 18±3 
7{2,2,3} > 100 10±2 
7{2,3,3} > 100 26±3 
9{2,4,2} > 100 27±7 
9{2,4,3} > 100 11±2 
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5. Binding curves for 9a{1,3,3} and 9b{1,3,3} at D1R and D2R.  
 
Figure S3. Binding curves of 9a{1,3,3} and 9b{1,3,3} at D1R (a) and D2R (b). Competition 
between D1R and D2R antagonists (i.e. [3H]-SCH 23390 and [3H]-YM 09151-2 respectively) 
and increasing concentrations of 9a{1,3,3} and 9b{1,3,3} were performed in brain striatal 
membranes as indicated in the Experimental Section. Non-specific binding was determined in 
the presence of 50 µM SCH 23390 or 50 µM YM 09151-2. Data are represented as means ± 
SD from a representative experiment (n = 3) performed in triplicates. 
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6. Full characterisation data for 9a{1,3,3} and 9b{1,3,3}. 
 
 
 
 
 
 
 
 
9a{1,3,3}: 17.2 mg, yellowish solid. 
HRMS: (m/z) [M+H+] calcd. for C42H57F2N8O5 791.4420, found: 791.4384. 
1H-NMR (400 MHz, MeOD): 7.39 (d, J=8.0 Hz, 1H, Ar), 7.29 (d, J=8.0 Hz, 1H, Ar), 7.21-
7.14 (m, 2H, Ar), 7.05 (t, J=6.8, 2H, Ar), 6.98 (t, J= 9 Hz, 1H, Ar), 4.57-4.53 (m, 1H), 4.35-
4.30 (m, 1H), 3.64-3.54 (m, 3H), 3.22-2.97 (m, 8H), 2.84-2.57 (m, 5H), 2.40 (t, J= 8.4 Hz, 
3H), 2.13-1.37 (m, 18H), 1.29 (bs, 1H), 1.21-0.98 (m, 1H) 
13C-NMR (101 MHz, MeOD): 175.3, 175.0, 174.4, 173.7, 149.5, 136.9, 135.1, 127.6, 127.1, 
125.7, 120.8, 120.8, 118.6, 118.1, 117.4, 117.0, 116.9, 110.6, 60.4, 60.2, 57.5, 54.8, 53.3, 
53.2, 51.9, 43.2, 40.2, 38.9, 35.9, 34.0, 31.4, 29.4, 29.3, 29.0, 28.3, 27.6, 26.4, 24.5, 24.2, 
22.8, 21.3. 
 
 
 
 
 
 
 
 
 
9b{1,3,3}: 14.2 mg, yellowish solid. 
HRMS: (m/z) [M+H+] calcd. for C42H57F2N8O5 791.4420, found: 791.4394. 
1H-NMR (400 MHz, MeOD): 7.38 (d, J=8.0 Hz, 1H, Ar), 7.28 (d, J=8.0 Hz, 1H, Ar), 7.19-
7.15 (m, 2H, Ar), 7.04 (td, J=7.8, 1.2 Hz, 2H, Ar), 6.96 (td, J=7.8, 1.2 Hz, 1H, Ar), 4.67 (dd, 
J=10.2, 5.2 Hz, 1H), 4.54 (dd, J=8.6, 6.0 Hz, 1H), 4.35-4.28 (m, 2H), 3.67-3.53 (m, 2H), 
3.22-2.86 (m, 7H), 2.77-2.56 (m, 5H), 2.38 (t, J=7.60 Hz, 2H), 2.14-1.39 (m, 19H), 1.29 (bs, 
1H), 0.98-0.85 (m, 1H). 
13C-NMR (101 MHz, MeOD): 176.2, 174.9, 174.9, 172.8, 138.1, 128.8, 128.3, 127.1, 126.9, 
122.0, 119.8, 119.3, 119.2, 118.6, 118.2, 111.9, 110.4, 107.8, 61.6, 61.3, 58.7, 55.9, 54.5, 
54.4, 44.4, 41.5, 41.3, 40.1, 37.1, 35.2, 32.6, 30.9, 30.5, 30.2, 29.4, 28.8, 27.6, 25.7, 25.3, 
23.9, 22.4. 
